JP4674046B2 - グルコース利用を刺激する化合物および使用方法 - Google Patents

グルコース利用を刺激する化合物および使用方法 Download PDF

Info

Publication number
JP4674046B2
JP4674046B2 JP2003580269A JP2003580269A JP4674046B2 JP 4674046 B2 JP4674046 B2 JP 4674046B2 JP 2003580269 A JP2003580269 A JP 2003580269A JP 2003580269 A JP2003580269 A JP 2003580269A JP 4674046 B2 JP4674046 B2 JP 4674046B2
Authority
JP
Japan
Prior art keywords
ethoxy
ethyl ester
acid
cyclopropanecarboxylic acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003580269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503801A5 (enExample
JP2006503801A (ja
Inventor
ギャリー デービッド ロパスチャック，
ジョン クリストファー ベデラス，
ジェイソン ローランド ダイク，
Original Assignee
ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/313,990 external-priority patent/US7074828B2/en
Application filed by ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ filed Critical ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ
Publication of JP2006503801A publication Critical patent/JP2006503801A/ja
Publication of JP2006503801A5 publication Critical patent/JP2006503801A5/ja
Application granted granted Critical
Publication of JP4674046B2 publication Critical patent/JP4674046B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/12—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
JP2003580269A 2002-04-01 2003-03-31 グルコース利用を刺激する化合物および使用方法 Expired - Fee Related JP4674046B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11204102A 2002-04-01 2002-04-01
US18127402A 2002-04-01 2002-04-01
IBPCT/IB02/02525 2002-04-01
US10/313,990 US7074828B2 (en) 2002-12-05 2002-12-05 Compounds that stimulate glucose utilization and methods of use
PCT/IB2003/001761 WO2003082800A1 (en) 2002-04-01 2003-03-31 Compounds that stimulate glucose utilization and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010003041A Division JP2010090166A (ja) 2002-04-01 2010-01-08 グルコース利用を刺激する化合物および使用方法

Publications (3)

Publication Number Publication Date
JP2006503801A JP2006503801A (ja) 2006-02-02
JP2006503801A5 JP2006503801A5 (enExample) 2006-05-25
JP4674046B2 true JP4674046B2 (ja) 2011-04-20

Family

ID=28678970

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003580269A Expired - Fee Related JP4674046B2 (ja) 2002-04-01 2003-03-31 グルコース利用を刺激する化合物および使用方法
JP2010003041A Withdrawn JP2010090166A (ja) 2002-04-01 2010-01-08 グルコース利用を刺激する化合物および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010003041A Withdrawn JP2010090166A (ja) 2002-04-01 2010-01-08 グルコース利用を刺激する化合物および使用方法

Country Status (5)

Country Link
EP (1) EP1499580B1 (enExample)
JP (2) JP4674046B2 (enExample)
AT (1) ATE551317T1 (enExample)
CA (1) CA2480557C (enExample)
WO (1) WO2003082800A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084173B2 (en) 2001-03-30 2006-08-01 The Governors Of The Univerity Of Alberta Compounds that stimulate glucose utilization and methods of use
US7524885B2 (en) 2002-04-01 2009-04-28 The Governors Of The University Of Alberta Compounds that stimulate glucose utilization and methods of use
ITRM20040346A1 (it) * 2004-07-13 2004-10-13 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US805704A (en) * 1905-05-24 1905-11-28 Andrew K Baltezor Trace-attaching member.
US3306727A (en) * 1962-03-16 1967-02-28 Gulf Oil Corp Weed control method and compositions therefor
US4000315A (en) * 1974-09-09 1976-12-28 Zoecon Corporation Cyclopropane esters for the control of mites
US3957849A (en) * 1974-09-09 1976-05-18 Zoecon Corporation Cyclopropane esters
CA1307787C (en) * 1986-06-11 1992-09-22 Melanie J. Loots Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
JPS6345252A (ja) * 1987-03-18 1988-02-26 Chugai Pharmaceut Co Ltd プロリン誘導体
DE3711268A1 (de) * 1987-04-03 1988-10-13 Basf Ag Cyclopropancarboxamide
CA2063822C (en) * 1989-07-18 2006-10-03 J. Gordon Foulkes Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
DE4103382A1 (de) * 1991-02-05 1992-08-06 Basf Ag Cyclopropancarbonsaeureamide und -thioamide, verfahren und zwischenprodukte zu ihrer herstellung sowie ihre verwendung zur schaedlingsbekaempfung
JPH05221945A (ja) * 1991-05-20 1993-08-31 Sumitomo Chem Co Ltd アミド誘導体、その製造法およびそれを有効成分とする有害生物防除剤
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
FR2734816B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux aryl (alkyl) propylamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19619036A1 (de) * 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
AU1631799A (en) * 1997-12-15 1999-07-05 Board Of Trustees Of The University Of Arkansas, The Fungicidal amides
US20030089885A1 (en) * 2001-04-25 2003-05-15 Senomyx, Inc. Use of low molecular weight acetal, alcohol, acylated alcohol and ester compounds to block or reduce odor of carboxylic acids

Also Published As

Publication number Publication date
CA2480557A1 (en) 2003-10-09
CA2480557C (en) 2013-02-19
WO2003082800A1 (en) 2003-10-09
HK1074435A1 (en) 2005-11-11
JP2006503801A (ja) 2006-02-02
ATE551317T1 (de) 2012-04-15
JP2010090166A (ja) 2010-04-22
EP1499580A1 (en) 2005-01-26
EP1499580B1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
JP2010180218A (ja) グルコース利用を刺激する化合物および使用方法
KR20030074809A (ko) 4-플루오로-ν-인단-2-일 벤즈아미드 및 약제로서의 이의용도
JP2014512333A (ja) 脂質低下抗糖尿病薬
JP4035759B2 (ja) アミノアルコールリン酸化合物、製造方法、及びその利用方法
US20090312286A1 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
JP2010090166A (ja) グルコース利用を刺激する化合物および使用方法
US7084173B2 (en) Compounds that stimulate glucose utilization and methods of use
US7074828B2 (en) Compounds that stimulate glucose utilization and methods of use
CN114349745B (zh) 一种用于治疗心肌缺血的药物及其制备方法
EP1277746B1 (fr) Nouveaux dérivés de N-benzylpiperazine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
HK1074435B (en) Compounds that stimulate glucose utilization and methods of use
HK1111141B (en) Compounds that stimulate glucose utilization and methods of use
US20250205193A1 (en) Therapeutic compound and salts
JP2006503801A5 (enExample)
TW202426428A (zh) 二苯基吡嗪類衍生物、其製備方法及應用
US20050159481A1 (en) Medicinal composition for improving angiotension-regulating function of blood vessel endothelium
HK1069398A (en) Medicinal composition for improving angiotension-regulating function of blood vessel endothelium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100510

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110112

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110124

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4674046

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140128

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees